

ANTIGENICS INC /DE/  
Form 8-K  
March 16, 2005

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934**

March 10, 2005  
Date of Report (Date of earliest event reported)

---

**ANTIGENICS INC.**  
(Exact name of registrant as specified in its charter)

**DELAWARE**  
(State or other jurisdiction  
of incorporation)

**000-29089**  
(Commission  
File Number)

**06-1562417**  
(IRS Employer  
Identification No.)

**630 Fifth Avenue, Suite 2100**  
**New York, NY 10111**  
(Address of principal executive offices)

**10111**  
(Zip Code)

**212-994-8200**  
(Registrant's telephone number, including area code)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 1.01** Entry into a Material Definitive Agreement

On March 10, 2005, the Board of Directors of Antigenics Inc. (the Company) ratified the recommendation of the Compensation Committee and awarded Garo Armen, Chairman and CEO, a cash bonus of \$174,300 under the Company's Executive Incentive Plan, a stock option grant of 300,000 shares under the Company's 1999 Equity Incentive Plan and set his base salary for 2005 at \$440,000. In addition, the Board of Directors ratified the recommendation of the Compensation Committee to award Pramod Srivastava, Founding Scientist, a cash bonus of \$135,000 and a stock option grant of 120,000 shares under the Company's 1999 Equity incentive Plan.

On February 10, 2005, the Compensation Committee awarded the following cash bonuses to the Company's named executives:

Peter Thornton, Sr. Vice-President and Chief Financial Officer	\$ 49,583
Russell Herndon, President, Commercial Operations	\$ 104,000
Renu Gupta, Sr. Vice-President, Development	\$ 117,000
Roman Chicz, Sr. Vice-President, Research & Preclinical development	\$ 39,750

All bonus awards are recommended based on achievement of goals and benchmark data.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ANTIGENICS INC.**

Date: March 16, 2005

By: /s/ Garo H. Armen

Garo H. Armen, Ph.D.  
Chairman and Chief Executive Officer